Antibody drug conjugates (ADC) that bind to FLT3 proteins
Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
1. An antibody or antigen binding fragment thereof that binds to FLT-3 comprising a CDRH1 having the amino acid sequence of SEQ ID NO:23, a CDRH2 having the amino acid sequence of SEQ ID NO:29, a CDRH3 having the amino acid sequence of SEQ ID NO:32, a CDRL1 having the amino acid sequence of SEQ ID NO: 14, a CDRL2 having the amino acid sequence of SEQ ID NO: 17, and a CDRL3 having the amino acid sequence of SEQ ID NO:20.
2. The antibody or antigen binding fragment thereof according to claim 1 , wherein the antibody comprises a heavy chain variable region consisting of the amino acid sequence ranging from 1 st E to the 123 rd S of SEQ ID NO: 11 and a light chain variable region consisting of the amino acid sequence ranging from 1 st D to the 108 th R of SEQ ID NO: 10.
3. The antibody or antigen binding fragment thereof according to claim 1 , wherein the antibody comprises a heavy chain variable region consisting of the amino acid sequence of the heavy chain variable region of an antibody produced by a Chinese Hamster Ovary (CHO) cell deposited under ATCC Accession No. PTA-121831 and a light chain variable region consisting of the amino acid sequence of the light chain of an antibody produced by a Chinese Hamster Ovary (CHO) deposited under ATCC. Accession No. PTA-121831.
4. The antibody or antigen binding fragment thereof according to claim 1 , wherein the antibody comprises an Fc region that is an IgG subtype.
5. The antibody or antigen binding fragment thereof according to claim 1 , wherein the Fc region comprises a substitution of a non-natural amino acid at amino acid position 124 of the heavy chain, and wherein the non-natural amino acid is para-acetylphenylalanine (pAF).
6. The antibody or antigen binding fragment thereof according to claim 1 , wherein the antibody comprises a heavy chain consisting of the amino acid sequence of amino acid numbers 1 st E to the 452 nd G of SEQ ID NO: 11 and a light chain consisting of the amino acid sequence ranging from the 1 st D to the 214 th C of SEQ ID NO: 10.
7. The antibody or antigen binding fragment thereof according to claim 1 , wherein the antibody comprises a heavy chain consisting of the amino acid sequence ranging from 1 st E to the 453 rd K of SEQ ID NO: 11 and a light chain consisting of the amino acid sequence ranging from 1 st D to the 214 th C of SEQ ID NO: 10.
8. The antibody or antigen binding fragment thereof according to claim 5 , wherein the antibody comprises a heavy chain consisting of the amino acid sequence of the heavy chain of an antibody produced by a Chinese Hamster Ovary (CHO) cell deposited under ATCC. Accession No. PTA-121836, and a light chain consisting of the amino acid sequence of the light chain of an antibody produced by a Chinese Hamster Ovary (CHO) deposited under ATCC. Accession No. PTA-121836.
9. The antibody or antigen binding fragment thereof according to claim 1 , wherein the 1 st amino acid of the heavy chain variable region or the heavy chain is pyroglutamate.
10. The antibody or antigen binding fragment thereof according to claim 1 , wherein the antibody comprises a heavy chain consisting of the amino acid sequence ranging from the 2 nd V to the 452 rd G of SEQ ID NO: 11, and wherein the 1 st amino acid of the heavy chain variable region or the heavy chain is pyroglutamate, and wherein the antibody comprises a light chain consisting of the amino acid sequence ranging from the 1 st D to the 214 th C of SEQ ID NO: 10.
11. An antigen-binding fragment comprising the CDRs of the antibody according to claim 1 , wherein the antigen-binding fragment binds FLT-3.
12. The antigen-binding fragment according to claim 11 , wherein the antigen-binding fragment is selected from the group consisting of Fab, Fab′, F(ab′)2, Fv, and scFv.
13. An isolated nucleic acid encoding the antibody or the antigen-binding fragment thereof according to claim 1 .
14. A expression vector comprising the isolated nucleic acid according to claim 13 .
15. A recombinant host cell comprising the the expression vector according to claim 14 .
16. An antibody or an antigen-binding fragment produced by culturing the recombinant host cell according to claim 15 .
17. An antibody drug conjugate comprising the antibody or the antigen binding fragment thereof according to claim 1 conjugated to a therapeutic agent via a linker.
18. The antibody drug conjugate according to claim 17 , wherein the linker is a non-cleavable linker.
19. The antibody drug conjugate according to claim 18 , wherein the linker is 2- (aminooxy) acetic acid.
20. The antibody drug conjugate of claim 17 , wherein the therapeutic agent is (2S,3S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-3-azido-N-methyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide.
21. The antibody drug conjugate of claim 17 , wherein the antibody drug conjugate has the following formula:
Antibody-(Linker-therapeutic agent) p ,
wherein the linker is 2-(aminooxy)acetic acid, wherein the therapeutic agent is (2S,3S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-3-azido-N-methyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide and, and wherein p is selected from the group consisting of 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, and 3.
22. A pharmaceutical composition comprising a therapeutically effective amount of the antibody drug conjugate according to claim 17 , and a pharmaceutically acceptable excipient.
23. The pharmaceutical composition according to claim 22 , further comprising one or more anti-neoplastic agents.
24. A method of treating cancer in a subject, comprising administering to said subject a therapeutically effective amount of an antibody drug conjugate according to claim 17 , wherein the cancer comprises cells that express FLT3.
25. The method according to claim 24 , wherein the cancer is selected from the group consisting of Acute Myeloid leukemia (AML), Acute Lymphoblastic leukemia (ALL), B-cell Lymphoblastic leukemia, and Precursor B-cell Lymphoblastic leukemia.
26. The method of claim 25 , wherein the cancer is AML.
27. The method of claim 25 , wherein the cancer is ALL.
28. The method of claim 25 , wherein the cancer is B-cell Lymphoblastic leukemia.
29. The method of claim 25 , wherein the cancer is Precursor B-cell Lymphoblastic leukemia.
30. A method of treating cancer in a subject, comprising administering to said subject the pharmaceutical composition according to claim 22 , wherein the cancer comprises cells that express FLT3.